COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00084565
Recruitment Status : Withdrawn (Study was never activated at Fox Chase Cancer Center.)
First Posted : June 11, 2004
Last Update Posted : July 10, 2013
Information provided by (Responsible Party):
Fox Chase Cancer Center

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving paclitaxel, topotecan, and estramustine together works in treating patients with metastatic hormone therapy-refractory prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: estramustine phosphate sodium Drug: paclitaxel Drug: topotecan hydrochloride Phase 2

Detailed Description:



  • Determine the objective response rate in patients with metastatic hormone-refractory prostate cancer treated with paclitaxel, topotecan, and estramustine.
  • Determine the progression-free and overall survival of patients treated with this regimen.
  • Determine the toxic effects of this regimen in these patients.
  • Determine the pharmacokinetics of this regimen in these patients.


  • Determine the frequency and number of circulating tumor cells in patients before and after treatment with this regimen and at disease progression.
  • Determine the microtubule morphology, β-tubulin isotype pattern, apoptotic markers, and metaphase chromosome alignment in circulating tumor cells in patients before and after treatment with this regimen and at disease progression.

OUTLINE: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15; topotecan IV over 30 minutes on days 2, 9, and 16; and oral estramustine twice daily on days 1 and 2 of course 1 and on days 0-2, 7-9, and 14-16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 18-38 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma
Study Start Date : November 2003
Actual Primary Completion Date : November 2004
Actual Study Completion Date : November 2004

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate gland

    • Progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or lung metastases)
    • Radiologic evidence of hydronephrosis alone dose not constitute metastatic disease
  • Failed prior primary hormonal therapy (e.g., estrogen therapy, luteinizing hormone-releasing hormone blocker and flutamide) or bilateral orchiectomy

    • Patients previously treated with flutamide or bicalutamide must have evidence of disease progression i.e., increasing Prostate-Specific Antigen (PSA)
  • PSA level ≥ 10 ng/mL if bone metastases only are present (i.e., lacking measurable soft tissue disease)
  • No elevated serum acid phosphatase or PSA level as the only evidence of disease
  • No carcinomatous meningitis or brain metastases



  • 18 and over

Performance status

  • Eastern Cooperative Oncology Group (ECOG) 0-2

Life expectancy

  • At least 12 weeks


  • White Blood Cell (WBC) ≥ 4,000/mm^3 OR
  • Granulocyte count ≥ 2,000/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Serum Glutamic-Oxaloacetic Transaminase(SGOT) and Serum Glutamic-Pyruvic Transaminase (SGPT) ≤ 2 times normal
  • Bilirubin ≤ 1.5 mg/dL


  • Creatinine ≤ 2.0 mg/dL OR
  • Creatinine clearance ≥ 50 mL/min


  • History of deep venous thrombosis allowed provided patients are maintained on therapeutic anticoagulation therapy
  • No active angina pectoris
  • No New York Heart Association class II-IV heart disease
  • No myocardial infarction within the past 6 months
  • No thrombosis within the past 3 months


  • Fertile patients must use effective contraception during and for 3 months after study participation
  • No active infection
  • No other concurrent serious medical illness that would preclude study participation
  • No other malignancy within the past 3 years except curatively treated basal cell or squamous cell skin cancer


Biologic therapy

  • Not specified


  • No prior chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 4 weeks since prior flutamide
  • At least 8 weeks since prior bicalutamide


  • More than 4 weeks since prior radiotherapy
  • No prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium


  • See Disease Characteristics


  • Recovered from all prior therapy
  • No prior cytotoxic therapy for prostate cancer
  • No concurrent milk, milk products, antacids, calcium-containing drugs, or food during estramustine administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00084565

Sponsors and Collaborators
Fox Chase Cancer Center
Layout table for investigator information
Principal Investigator: Gary R. Hudes, MD Fox Chase Cancer Center
Layout table for additonal information
Responsible Party: Fox Chase Cancer Center Identifier: NCT00084565    
Other Study ID Numbers: FCCC-03035
CDR0000365459 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 11, 2004    Key Record Dates
Last Update Posted: July 10, 2013
Last Verified: July 2013
Keywords provided by Fox Chase Cancer Center:
stage IV prostate cancer
adenocarcinoma of the prostate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Antineoplastic Agents, Hormonal